Top

Published in:

01-05-2016 | Case Report

Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports

Authors: B. Aubry-Rozier, E. Gonzalez-Rodriguez, D. Stoll, O. Lamy

Published in: Osteoporosis International | Issue 5/2016

Abstract

Osteoporosis treatments are usually given for a limited period of time in order to balance benefits and risks. We report three cases of postmenopausal women without any previous fragility fracture who presented severe spontaneous vertebral fractures after denosumab discontinuation. We think that the occurrence of these fractures could be explained by the severe rebound effect observed after denosumab discontinuation and that a consensus regarding the end of treatment with denosumab has to be defined.

Roux C, Briot K (2014) How long should we treat? Osteoporos Int 25:1659–66CrossRefPubMed

De Villiers TJ, Gass ML, Haines CJ et al (2013) Global consensus statement on menopausal hormone therapy. Climacteric 16:203–4CrossRefPubMed

Neele SJ, Evertz R, De Valk-DeRoo G, Roos JC, Netelenbos JC (2002) Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone 30:599–603CrossRefPubMed

Gallagher JC, Rapuri PB, Haynatzki G, Detter JR (2002) Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. J Clin Endocrinol Metab 87:4914–23CrossRefPubMed

Bone HG, Bolognese MA, Yuen CK et al (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turn-over markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96:972–80CrossRefPubMed

Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial. JAMA 296:2927–38CrossRefPubMed

Black DM, Reid IR, Boonen S et al (2012) The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 27:243–54CrossRefPubMedPubMedCentral

Prince R, Sipos A, Hossain A et al (2005) Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 20:1507–1513CrossRefPubMed

Watts NB, Chines A, Olszynski WP et al (2008) Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 19:365–72CrossRefPubMed

10.

Yates J, Barrett-Connor E, Barlas S, Chen YT, Miller PD, Siris ES (2004) Rapid loss of hip fracture protection after estrogen cessation: evidence from the national osteoporosis risk assessment. Obstet Gynecol 103:440–6CrossRefPubMed

11.

LaCroix AZ, Chlebowski RT, Manson JE et al (2011) Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 305:1305–14CrossRefPubMedPubMedCentral

12.

Manson JE, Chlebowski RT, Stefanick ML et al (2013) Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trial. JAMA 310(13):1353–68CrossRefPubMed

13.

Brown JP, Roux C, Törring O et al (2013) Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial. J Bone Miner Res 28:746–52CrossRefPubMedPubMedCentral

14.

McClung MR, Lewiecki EM, Geller ML et al (2013) Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int 24:227–35CrossRefPubMedPubMedCentral

15.

S. Papapoulos S, Lippuner K, Roux C et al (2015) The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM extension study” Bone. Osteoporos Int

Title: Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports
Authors: B. Aubry-Rozier
E. Gonzalez-Rodriguez
D. Stoll
O. Lamy
Publication date: 01-05-2016
Publisher: Springer London
Published in: Osteoporosis International / Issue 5/2016
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-015-3380-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2016

Serum calcium and incident diabetes: an observational study and meta-analysis

Risk of cardiac valvulopathy with use of bisphosphonates: a population-based, multi-country case-control study

Mechanisms of vasodilation to PTH 1–84, PTH 1–34, and PTHrP 1–34 in rat bone resistance arteries

Bone matrix mineralization is preserved during early perimenopausal stage in healthy women: a paired biopsy study

Bisphosphonates for prevention of osteopenia in kidney-transplant recipients: a systematic review of randomized controlled trials

Cancel the denosumab holiday